Pharmacogenomics of endocrine therapy in breast cancer

Journal of Human Genetics

Volumn 58, Issue 6, 2013, Pages 306-312

  Ingle, James N ^a  

^a MAYO CLINIC   (United States)

Author keywords

aromatase inhibitors; breast cancer; pharmacogenomics; tamoxifen

Indexed keywords

ANASTROZOLE; CELECOXIB; EXEMESTANE; FULVESTRANT; TAMOXIFEN;

ARTICLE; BONE DENSITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; DISEASE FREE SURVIVAL; DISEASE SPECIFIC SURVIVAL; EVENT FREE SURVIVAL; FRAGILITY FRACTURE; FUNCTIONAL GENOMICS; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PHENOTYPE; POSTMENOPAUSE; SINGLE NUCLEOTIDE POLYMORPHISM;

ANDROSTADIENES; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; JAPAN; MUSCULOSKELETAL PHYSIOLOGICAL PHENOMENA; NITRILES; PHARMACOGENETICS; PHENOTYPE; POSTMENOPAUSE; RALOXIFENE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TRIAZOLES;

EID: 84880866178     PISSN: 14345161     EISSN: 1435232X     Source Type: Journal    
DOI: 10.1038/jhg.2013.35     Document Type: Article

References (42)

1. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2013. CA Cancer J. Clin. 63, 11-30 (2013).
2. NationalCancerCenter. Cancer Statistics in Japan '2010 (Foundation for Promotion of Cancer Research, Tokyo, Japan, 2010).
3. Early Breast Cancer Trialists' Collaborative Group. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level metaanalysis of randomised trials. Lancet. 378, 771-784 (2011).
4. Ingle, J. N. Overview of adjuvant trials of aromatase inhibitors in early breast cancer. Steroids 76, 765-767 (2011).
5. Dowsett, M., Cuzick, J., Ingle, J., Coates, A., Forbes, J., Bliss, J. et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J. Clin. Oncol. 28, 509-518 (2010).
6. Burstein, H. J., Prestrud, A. A., Seidenfeld, J., Anderson, H., Buchholz, T. A., Davidson, N. E. et al. American Society of Clinical Oncology Clinical Practice Guideline: update on adjuvant endocrine therapy for women with hormone receptorpositive breast cancer. J. Clin. Oncol. 28, 3784-3796 (2010).
7. Cuzick, J., Powles, T., Veronesi, U., Forbes, J., Edwards, R., Ashley, S. et al. Overview of the main outcomes in breast-cancer prevention trials. The Lancet 361, 296-300 (2003). (Pubitemid 36126189)
8. Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M. et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 90, 1371-1388 (1998). (Pubitemid 28439961)
9. Vogel, V. G., Costantino, J. P., Wickerham, D., Cronin, W. M., Cecchini, R. S., Atkins, J. N. et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. JAMA 295, 2727-2741 (2006).
10. Vogel, V. G., Costantino, J. P., Wickerham, D. L., Cronin, W. M., Cecchini, R. S., Atkins, J. N. et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev. Res. 3, 696-706 (2010).
11. Ingle, J. N., Buzdar, A. U., Schaid, D. J., Goetz, M. P., Batzler, A., Robson, M. E. et al. Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer. Cancer Res. 70, 3278-3286 (2010).
12. Offit, K. & Robson, M. E. New pharmacogenomic paradigm in breast cancer treatment. J. Clin. Oncol. 28, 4665-4666 (2010).
13. Ingle, J. N., Schaid, D. J., Goss, P. E., Liu, M., Mushiroda, T., Chapman, J. A. et al. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J. Clin. Oncol. 28, 4674-4682 (2010).
14. Goss, P. E., Ingle, J. N., Pritchard, K. I., Ellis, M. J., Sledge, G. W., Budd, G. T. et al. Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27-a randomized controlled phase III trial. J. Clin. Oncol. 31 (11), 1398-1404 (2013).
15. Partridge, A. H., LaFountain, A., Mayer, E., Taylor, B. S., Winer, E. & Asnis-Alibozek, A. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J. Clin. Oncol. 26, 556-562 (2008). (Pubitemid 351264348)
16. Crew, K. D., Greenlee, H., Capodice, J., Raptis, G., Brafman, L., Fuentes, D. et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J. Clin. Oncol. 25, 3877-3883 (2007). (Pubitemid 47477264)
17. Henry, N. L., Giles, J. T., Ang, D., Mohan, M., Dadabhoy, D., Robarge, J. et al. Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res. Treat. 111, 365-372 (2008).
18. Niu, N., Qin, Y., Fridley, B. L., Hou, J., Kalari, K. R., Zhu, M. et al. Radiation pharmacogenomics: a genome-wide association approach to identify radiation response biomarkers using human lymphoblastoid cell lines. Genome Res. 20, 1482-1492 (2010).
19. Li, L., Fridley, B., Kalari, K., Jenkins, G., Batzler, A., Safgren, S. et al. Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression. Cancer Res. 68, 7050-7058 (2008).
20. Miossec, P., Korn, T. & Kuchroo, V. K. Interleukin-17 and type 17 helper T cells. N. Engl. J. Med. 361, 888-898 (2009).
21. Liu, M., Wang, L., Bongartz, T., Hawse, J. R., Markovic, S. N., Schaid, D. J. et al. Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression. Breast Cancer Res. 14, R41 (2012).
22. Bokarewa, M., Nagaev, I., Dahlberg, L., Smith, U. & Tarkowski, A. Resistin, an adipokine with potent proinflammatory properties. J. Immunol. 174, 5789-5795 (2005).
23. Cummings, S. R. & Melton, L. J. III. Epidemiology and outcomes of osteoporotic fractures. Lancet 359, 1761-1767 (2002).
24. Johnell, O. & Kanis, J. A. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos. Int. 17, 1726-1733 (2006). (Pubitemid 44607392)
25. Finkelstein, J. S., Brockwood, S. E., Mehta, V., Greendale, G. A., Sowers, M. R., Ettinger, B. et al. Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J. Clin. Endocrinol. Metab. 93, 861-868 (2008). (Pubitemid 351398564)
26. Ferrari, S. Human genetics of osteoporosis. Best. Pract. Clin. Endocrinol. Metab. 22, 723-735 (2008).
27. Estrada, K., Styrkarsdottir, U., Evangelou, E., Hsu, Y.-H., Duncan, E. L., Ntzani, E. E. et al. Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat. Genet. 44, 491-501 (2012).
28. Eastell, R. & Hannon, R. Long-term effects of aromatase inhibitors on bone. J. Steroid Biochem. Molec. Biol. 95, 151-154 (2005). (Pubitemid 41137305)
29. Chien, A. J. & Goss, P. E. Aromatase inhibitors and bone health in women with breast cancer. J. Clin. Oncol. 24, 5305-5312 (2006). (Pubitemid 46631378)
30. Khosla, S. Increasing options for the treatment of osteoporosis. N. Engl. J. Med. 361, 818-820 (2009).
31. Hudis, C. A., Barlow, W. E., Costantino, J. P., Gray, R. J., Pritchard, K. I., Chapman, J. W. et al. proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J. Clin. Oncol. 25, 2127-2132 (2007). (Pubitemid 46972801)
32. Simpson, E. R., Mahendroo, M. S., Means, G. D., Kilgore, M. W., Hinshelwood, M. M., Graham-Lorrence, S. et al. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr. Rev. 15, 342-355 (1994). (Pubitemid 24180792)
33. Ma, C. X., Adjei, A. A., Salavaggione, O. E., Coronel, J., Pelleymounter, L., Wang, L. et al. Human aromatase: gene resequencing and functional genomics. Cancer. Res. 65, 11071-11082 (2005). (Pubitemid 41713378)
34. Liu, M., Ingle, J. N., Fridley, B. L., Buzdar, A. U., Robson, M. E., Kubo, M. et al. TSPYL5 SNPs: Association with plasma estradiol concentrations and aromatase expression. Mol. Endocrinol. 4, 657-670 (2013).
35. Durbin, R. M., Abecasis, G. R., Altshuler, D. L., Auton, A., Brooks, L. D., Gibbs, R. A. et al. A map of human genome variation from population-scale sequencing. Nature 467, 1061-1073 (2010).
36. Wang, L., Ellsworth, K. A., Moon, I., Pelleymounter, L. L., Eckloff, B. W., Martin, Y. N. et al. Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors. Cancer Res. 70, 319-328 (2010).
37. Bulun, S. E., Sebastian, S., Takayama, K., Suzuki, T., Sasano, H. & Shozu, M. The human CYP19 (aromatase P450) gene: update on physiologic roles and genomic organization of promoters. J. Steroid. Biochem. Mol. Biol. 86, 219-224 (2003). (Pubitemid 37412560)
38. Ropka, M. E., Keim, J. & Philbrick, J. T. Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis. J. Clin. Oncol. 28, 3090-3095 (2010).
39. Armstrong, K., Quistberg, D., Micco, E., Domchek, S. & Guerra, C. Prescription of tamoxifen for breast cancer prevention by primary care physicians. Archiv. Int. Med. 166, 2260-2265 (2006). (Pubitemid 44748773)
40. Ingle, J. N., Liu, M., Wickerham, D. L., Schaid, D. J., Mushiroda, T., Kubo, M. et al. Genome-wide associations of breast events and functional genomic studies in high-risk women receiving tamoxifen or raloxifene on NSABP P1 and P2 prevention trials. A Pharmacogenomics Research Network-RIKEN-NSABP Collaboration. Cancer Res. 70 (24 Suppl), 110s (2010).
41. Ingle, J. N., Liu, M., Wickerham, D. L., Schaid, D. J., Wang, L., Mushiroda, T. et al. Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention. Cancer Discov. (in press).
42. Goetz, M. P., Schaid, D. J., Wickerham, D. L., Safgren, S., Mushiroda, T., Kubo, M. et al. Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials. Clin. Cancer Res. 17, 6944-6951 (2011).